Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

181. Research on the value of the T cell spot test for tuberculosis for the diagnosis of lung cancer combined with pulmonary tuberculosis Full Text available with Trip Pro

Research on the value of the T cell spot test for tuberculosis for the diagnosis of lung cancer combined with pulmonary tuberculosis This study was conducted to investigate the value of the T cell spot test for tuberculosis (T-SPOT.TB) for the diagnosis of patients with lung cancer combined with pulmonary tuberculosis (LCTB).Thirty-six patients diagnosed with LCTB who received treatment at Shandong Provincial Chest Hospital from September 2014 to 2017 were randomly chosen and enrolled (...) clinical application.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

2018 Thoracic cancer

182. Significance of spread through air spaces in early‐stage lung adenocarcinomas undergoing limited resection Full Text available with Trip Pro

postoperative survival in patients with early-stage adenocarcinomas treated with limited resection and was associated with surgical margin recurrence.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. (...) Significance of spread through air spaces in early‐stage lung adenocarcinomas undergoing limited resection In early-stage lung adenocarcinomas, spread through air spaces (STAS) are reported to be a prognostic factor in patients who have undergone sublobar resection, but not lobectomy. In contrast, reports have also shown that STAS is significantly associated with poor survival outcomes after lobectomy, but not after limited resection. Thus, the prognostic impact of STAS differs according

2018 Thoracic cancer

183. Surgically treated lung cancer patients: do they all smoke and would they all have been detected with lung cancer screening? Full Text available with Trip Pro

Surgically treated lung cancer patients: do they all smoke and would they all have been detected with lung cancer screening? Since publication of the National Lung Cancer Screening Trial (NLST) results early lung cancer detection has been widely studied, targeting individuals based on smoking history and age. However, over recent decades several changes in lung cancer epidemiology, including risk factors, have taken place. The aim of the current study was to explore smoking prevalence among (...) lung cancer patients who had been treated surgically or undergone a diagnostic operation and whether these patients would have met the NLST inclusion criteria. All patients operated on for lung cancer in a university hospital in Estonia between 2009 and 2015 were included. Data were collected from hospital records. 426 patients were operated on for lung cancer, with smoking history properly documented in 327 patients (87 females; median age 67 years). 170 (52%) patients were smokers, 97 (30

2018 ERJ open research

184. Lung cancer

• Primary cutaneous lymphoma • Acute myeloblastic leukaemia in adult patients • Waldenstrom's macroglobulinaemia • Gastric marginal zone lymphoma of MALT type Head and Neck Cancers Nasopharyngeal Cancer • Squamous-Cell Carcinoma of the Head and Neck Hereditary Syndromes Prevention and Screening in BRCA Mutation Carriers and Other Breast/Ovarian Hereditary Cancer Syndromes Lung and Chest Tumours Early and locally 2017 9. Tobacco Dependence Predicts Higher Lung Cancer and Mortality Rates and Lower Rates (...) in the United States and accounts for as many cancer deaths as breast, prostate, colon, and pancreatic cancer combined. Every year, 160,000 patients will die from lung cancer [2]. Nearly 60% of patients will have metastatic disease at the time of diagnosis and the [3]. An effective screening test for lung cancer could significantly improve survival rates 2014 4. Clinical practice guidelines for the treatment of lung cancer Summary of recommendations - Cancer Guidelines Wiki Skip Links Personal tools Search

2018 Trip Latest and Greatest

185. Tobacco Dependence Predicts Higher Lung Cancer and Mortality Rates and Lower Rates of Smoking Cessation in the National Lung Screening Trial Full Text available with Trip Pro

Tobacco Dependence Predicts Higher Lung Cancer and Mortality Rates and Lower Rates of Smoking Cessation in the National Lung Screening Trial Incorporating tobacco treatment within lung cancer screening programs has the potential to influence cessation in high-risk smokers. We aimed to better understand the characteristics of smokers within a screening cohort, correlate those variables with downstream outcomes, and identify predictors of continued smoking.This study is a secondary analysis (...) of the National Lung Screening Trial randomized clinical study. Tobacco dependence was evaluated by using the Fagerstrӧm Test for Nicotine Dependence, the Heaviness of Smoking Index, and time to first cigarette (TTFC); descriptive statistics were performed. Clinical outcomes (smoking cessation, lung cancer, and mortality) were assessed with descriptive statistics and χ2 tests stratified according to nicotine dependence. Logistic and Cox regression models were used to study the influence of dependence

2018 EvidenceUpdates

186. Incorporating Coexisting Chronic Illness into Lung Cancer Screening: A Research Statement

, Jul 15, 2018 Copyright© 2018 by the American Thoracic Society DOI: 10.1164/rccm.201805-0986ST Internet address: www.atsjournals.org American Thoracic Society Documents e3 Overview An ef?cacious screening test must identify disease with high prevalence, mortality, and cure rate when detected at an early stage in individuals who are healthy enough to undergo effective treatment. Lung cancer screening (LCS) with annual low-dose computed tomography (LDCT) satis?es these criteria, and if implemented (...) correctly, it may be the single intervention, other than quitting smoking, with the largest effect on decreasing cancer deaths in our lifetime. The NLST (National Lung Screening Trial), however, which provides the evidence for LCS, suffers from the “healthy volunteer effect.” This phenomenon,inwhichparticipantsarebetter educated, younger, and have less comorbid disease than the general population that would otherwise qualify for LCS, is commonly seen in screening trials and draws concerns about

2018 American Thoracic Society

187. Alectinib for untreated ALK-positive advanced non-small-cell lung cancer

with crizotinib. There is uncertainty about how treatments after disease progression affect people's quality and length of life. But using the most plausible assumptions and with the commercial arrangement, the cost-effectiveness estimates for alectinib compared with crizotinib are within the range NICE normally considers acceptable. Therefore, alectinib is recommended for untreated advanced ALK- positive NSCLC. Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536) © NICE 2018. All (...) lung cancer 3.1 People with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) tend to be younger and are less likely to have a history of smoking than the wider NSCLC population. As a result, people with ALK- positive disease may be less likely to be included in lung cancer screening programmes. The committee understood that approximately 40% to 50% of all people with NSCLC develop central nervous system (CNS) metastases, which can reduce quality of life and survival

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

188. Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer

use as an option for people with untreated PD-L1-positive metastatic NSCLC (with at least a 50% tumour proportion score) and no EGFR- or ALK-positive tumour mutations, only if pembrolizumab is stopped at 2 years of uninterrupted treatment, or earlier in the event of disease progression, and if the company provides pembrolizumab according to the commercial access agreement. Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531) © NICE 2018. All rights reserved (...) ://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 19This guidance replaces TA447. 1 1 Recommendation Recommendation 1.1 Pembrolizumab is recommended as an option for untreated PD-L1-positive metastatic non-small-cell lung cancer (NSCLC) in adults whose tumours express PD-L1 (with at least a 50% tumour proportion score) and have no epidermal growth factor receptor- or anaplastic lymphoma kinase-positive mutations, only if: pembrolizumab is stopped at 2 years of uninterrupted treatment

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

189. Alectinib hydrochloride (Alecensa) - anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)

an ALK fusion protein that contributes to increased cell proliferation and survival in tumours expressing these genes. ALK positive tumours tend to be associated with younger patients, adenocarcinoma histology and history of never or light smoking, with relatively higher incidence in females. Advanced ALK-positive NSCLC has a high risk of CNS metastases and the CNS is the most common site for disease progression. There is substantial morbidity associated with CNS metastases, and their treatment (...) Alectinib hydrochloride (Alecensa) - anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) 1 alectinib 150mg hard capsules (Alecensa ® ) SMC2012 Roche Products Limited 6 July 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following a full submission assessed under

2018 Scottish Medicines Consortium

190. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer (Abstract)

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer Purpose The phase III PROFILE 1014 trial compared crizotinib with chemotherapy as first-line treatment in patients with anaplastic lymphoma kinase (ALK) -positive advanced nonsquamous non-small-cell lung cancer. Here, we report the final overall survival (OS) results. Patients and Methods Patients were randomly assigned to receive oral crizotinib (...) that favored crizotinib (hazard ratio, 0.346; 95% bootstrap CI, 0.081 to 0.718). The longest OS was observed in crizotinib-treated patients who received a subsequent ALK tyrosine kinase inhibitor. No new safety signals were identified. Conclusion The final analysis of the PROFILE 1014 study provides a new benchmark for OS in patients with ALK-rearranged non-small-cell lung cancer and highlights the benefit of crizotinib for prolonging survival in this patient population.

2018 EvidenceUpdates

191. Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study Full Text available with Trip Pro

Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study Purpose The purpose of the current study was to investigate whether prophylactic cranial irradiation (PCI) reduces the incidence of symptomatic brain metastases in patients with stage III non-small-cell lung cancer (NSCLC) treated with curative intention. Patients and Methods Patients with stage III NSCLC-staged with a contrast-enhanced

2018 EvidenceUpdates

192. Correlation between radiomic features based on contrast‐enhanced computed tomography images and Ki‐67 proliferation index in lung cancer: A preliminary study Full Text available with Trip Pro

features were extracted from preoperative contrast-enhanced chest multidetector CT images for each tumor using open-source three-dimensional Slicer software. Statistical analysis was performed to determine significant radiomic features serving as image predictors of Ki-67 status in lung cancer and to investigate the relationship between these features and Ki-67 PI.Higher Ki-67 expression was more common in men (P = 0.02) and patients with a smoking history (P = 0.01). Twelve radiomic features were (...) Correlation between radiomic features based on contrast‐enhanced computed tomography images and Ki‐67 proliferation index in lung cancer: A preliminary study The purpose of the study was to investigate the association between radiomic features based on contrast-enhanced multidetector computed tomography (CT) and the Ki-67 proliferation index (PI) in patients with lung cancer.One hundred and ten patients with lung cancer confirmed by surgical histology were retrospectively included. Radiomic

2018 Thoracic cancer

193. Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer Full Text available with Trip Pro

 = 0.005).TOPO1 expression was prevalent in SCLC patients. Strong expression was associated with an elevated disease control rate after second-line topotecan chemotherapy. Patients with sensitive disease that relapsed after first-line chemotherapy had better survival than refractory patients who received second-line topotecan chemotherapy.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. (...) Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer We evaluated topoisomerase I (TOPO1) expression in patients with small cell lung cancer (SCLC) and identified predictive factors for the efficacy of second-line topotecan chemotherapy.We retrospectively evaluated the records of SCLC patients treated in our department from January 2007 to December 2016 who received second-line topotecan chemotherapy

2018 Thoracic cancer

194. Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts Full Text available with Trip Pro

Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts The combination of EGFR tyrosine kinase inhibitors (TKIs) and chemotherapy is thought to increase treatment efficacy in non-small-cell lung cancer (NSCLC). This study investigated the efficacy and potential mechanisms of different combined modes of icotinib plus pemetrexed in EGFR-mutant lung adenocarcinoma cell line xenograft models.Nude mice were subcutaneously injected with EGFR-mutant human (...) lung adenocarcinoma cells (HCC827) and randomized into six treatment groups. Tumor xenograft volumes were monitored and recorded. Microvessel density (MVD) and proliferation and apoptosis rates were evaluated with CD34 positive cell counting, and Ki-67 and caspase-3 scores, respectively, and determined via immunohistochemistry. Thymidylate synthase (TS), EGFR, and downstream signaling molecule expression was detected by Western blotting.The volume and weight of tumor xenografts in the sequential

2018 Thoracic cancer

195. Overexpression of S100A13 protein is associated with tumor angiogenesis and poor survival in patients with early‐stage non‐small cell lung cancer Full Text available with Trip Pro

Overexpression of S100A13 protein is associated with tumor angiogenesis and poor survival in patients with early‐stage non‐small cell lung cancer S100A13 plays a key role in tumor growth and metastasis. The purpose of this study was to investigate the prognostic significance of S100A13 expression, microvessel density (MVD), and survival in early stage non-small cell lung cancer (NSCLC).In silico analysis was performed to determine the associations between S100A13 and NSCLC. The data of 82 (...) was significantly higher in tumors with high (67.6%, 25/37) compared to low S100A13 expression (13.3%, 6/45) (P < 0.01).High S100A13 expression is closely associated with high intratumoral angiogenesis and poor prognosis in patients with stage I NSCLC. Immunohistochemical evaluation of S100A13 expression, along with an examination of the perioperative extent of angiolymphatic invasion, has value for predicting prognosis.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley

2018 Thoracic cancer

196. Stereotactic Body Radiation Therapy for Biopsy-Proven Primary Non–Small-Cell Lung Cancer: Experience of Patients With Inoperable Cancer at a Single Brazilian Institution Full Text available with Trip Pro

Stereotactic Body Radiation Therapy for Biopsy-Proven Primary Non–Small-Cell Lung Cancer: Experience of Patients With Inoperable Cancer at a Single Brazilian Institution Purpose Stereotactic body radiation therapy (SBRT) has emerged as a treatment option for patients with non-small-cell lung cancer (NSCLC). We report the clinical outcomes and toxicity for patients with inoperable primary NSCLC treated with SBRT. Methods Between 2007 and 2015, 102 consecutive lung lesions were treated (...) Most of the 54 patients were men (n = 41; 76%), median age was 75 years; stage IA (n = 36; 66%) and adenocarcinoma (n = 43; 80%) were the most common stage and histologic diagnosis, respectively. Five patients had two lung lesions. A median of three fractions (range, 3 to 5 fractions) and a total median dose of 54 Gy (range, 45 to 60 Gy) per lesion were prescribed. The median follow-up was 17.8 months (range, 4 to 56.4 months). The 2-year rates of LC, regional or distant failure-free survival

2018 Journal of global oncology

197. Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity Full Text available with Trip Pro

Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity Nivolumab is used at 3 mg/kg or fixed doses of 240 mg every 2 weeks. There was no dose-response/toxicity relationship of nivolumab. This study evaluated the efficacy of low-dose nivolumab as an alternative to the financial toxicity of standard-dose nivolumab in treatment of non-small cell lung cancer (NSCLC).Outcomes of patients with NSCLC treated with nivolumab as a routine practice

2018 ESMO open

198. CSF-1 and Ang-2 serum levels — prognostic and diagnostic partners in non-small cell lung cancer Full Text available with Trip Pro

CSF-1 and Ang-2 serum levels — prognostic and diagnostic partners in non-small cell lung cancer Lung cancer is the most incident and lethal form of cancer, with late diagnosis as a major determinant of its bad prognosis. Immunotherapies targeting immune checkpoints improve survival, but positive results encompass only 30%-40% of the patients, possibly due to alternative pathways to immunosuppression, including tumour-associated macrophages (TAM). Colony stimulating factor-1 (CSF-1 (...) ) is implicated in TAM differentiation and recruitment to tumours and in tumour angiogenesis, through a special setting of Tie-2-expressing macrophages, which respond to angiopoietin-2 (Ang-2). We evaluated the role of serum levels of CSF-1 in non-small cell lung cancer (NSCLC) prognosis and whether these could serve as biomarkers for NSCLC detection, along with Ang-2.We prospectively studied an unselected cohort of 145 patients with NSCLC and a group of 30 control individuals. Serum levels of Ang-2 and CSF-1

2018 ESMO open

199. Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer) Full Text available with Trip Pro

Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer) This single-arm phase II trial aimed to evaluate a stop-and-go strategy with cisplatin-based chemotherapy and bevacizumab in advanced non-squamous non-small cell lung cancer (NSCLC).Patients were initially treated with three cycles of pemetrexed, cisplatin plus bevacizumab (...) (86%) received the three planned cycles including 37 (56.9%, 95% CI 45.1 to 73.6) without platinum dose reduction. The median progression-free survival 1 (PFS1; inclusion to progression 1) was 5.6 months (95% CI 5.0 to 6.3) and median PFS2 (progression 1 to progression 2) was 6.8 months (95% CI 5.8 to 8.8). The median disease control duration (PFS1+PFS2; n=65) was 12.4 months (95% CI 11.2 to 14.9). The median overall survival was 17.7 months (95% CI 13.1 to 21.6) and 20.5 months (95% CI 16.9

2018 ESMO open

200. Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non‐T790M mutations after progression on first‐line EGFR‐tyrosine kinase inhibitors Full Text available with Trip Pro

-positive lung adenocarcinoma who had received second-line PC with or without bevacizumab harboring EGFR non-T790M mutations after progression on first-line EGFR-TKIs between April 2015 and 2017 at Tianjin Medical University Cancer Institute and Hospital were enrolled in the study. The primary endpoint was progression-free survival and secondary endpoints were overall survival, objective response rate, disease control rate, and safety.A total of 85 patients were eligible for the study: 55 and 30 cases (...) and proteinuria but did not require the discontinuation of therapy.The addition of bevacizumab to PC was superior to PC alone as second-line therapy in patients with advanced non-T90M EGFR-positive lung adenocarcinoma. However, this result needs to be confirmed by prospective clinical trials.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

2018 Thoracic cancer